Korro Bio, Inc. (KRRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Korro Bio, Inc. (KRRO) has a cash flow conversion efficiency ratio of -0.134x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.07 Million) by net assets ($119.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View KRRO share price today for real-time trading data and today's change.
Korro Bio, Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Korro Bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Korro Bio, Inc. market capitalisation for the company's overall valuation and market capitalisation.
Korro Bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Korro Bio, Inc. ranked by their cash flow conversion efficiency. Also see KRRO current and non-current assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ellington Residential Mortgage
NYSE:EARN
|
0.569x |
|
Imagesat International ISI Ltd
TA:ISI
|
0.108x |
|
Petronor E&P Ltd
OL:PNOR
|
-0.047x |
|
A Paradise Acquisition Corp.
NYSE:APAD
|
-0.001x |
|
Sahamitr Pressure Container Public Company Limited
BK:SMPC
|
0.019x |
|
Premia S.A.
AT:PREMIA
|
0.007x |
|
Smartbroker Holding AG
XETRA:SB1
|
-0.051x |
|
Astra Graphia Tbk
JK:ASGR
|
0.006x |
Annual Cash Flow Conversion Efficiency for Korro Bio, Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Korro Bio, Inc. from 2017 to 2025. Review how financially flexible is Korro Bio, Inc. to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $51.44 Million | $-78.56 Million | -1.527x | -307.82% |
| 2024-12-31 | $160.41 Million | $-60.07 Million | -0.374x | +5.43% |
| 2023-12-31 | $169.91 Million | $-67.28 Million | -0.396x | -173.10% |
| 2022-12-31 | $-99.03 Million | $-53.65 Million | 0.542x | +320.81% |
| 2021-12-31 | $130.82 Million | $-32.09 Million | -0.245x | -4.50% |
| 2020-12-31 | $192.49 Million | $-45.19 Million | -0.235x | -214.83% |
| 2019-12-31 | $167.36 Million | $34.22 Million | 0.204x | -46.55% |
| 2018-12-31 | $-44.51 Million | $-17.02 Million | 0.382x | -22.42% |
| 2017-12-31 | $-29.64 Million | $-14.61 Million | 0.493x | -- |
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate … Read more